BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38308719)

  • 1. Comparing heuristic valuation processes between health state valuation from child and adult perspectives.
    Lipman SA; Reckers-Droog VT
    Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38308719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
    Lipman SA; Zhang L; Shah KK; Attema AE
    Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
    Che M; Pullenayegum E
    Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.
    Lipman SA; Essers BAB; Finch AP; Sajjad A; Stalmeier PFM; Roudijk B
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):181-192. PubMed ID: 36255560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
    Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
    Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A direct comparison between discrete choice with duration and composite time trade-off methods: do they produce similar results?
    Roudijk B; Jonker MF; Bailey H; Pullenayegum E
    Value Health; 2024 Jun; ():. PubMed ID: 38843979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
    Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expect Nothing: The (Lack of) Influence of Subjective Life Expectancy on Valuation of Child Health States.
    Lipman SA
    Front Health Serv; 2022; 2():803109. PubMed ID: 36925864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study.
    Doherty E; Hobbins A; Whitehurst DGT; O'Neill C
    Pharmacoecon Open; 2021 Jun; 5(2):237-244. PubMed ID: 33481204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of duration and time preference on the gap between adult and child health state valuations in time trade-off.
    Lang Z; Attema AE; Lipman SA
    Eur J Health Econ; 2024 Jun; 25(4):601-613. PubMed ID: 37420133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.